Health-related quality of life profile of patients with immune thrombocytopenia in the real life is impaired by splenectomy

Annals of Hematology - Tập 101 - Trang 749-754 - 2022
Giovanni Caocci1, Fabio Efficace2, Olga Mulas1, Francesco Cottone2, Alessia Maxia1, Alessandro Costa1, Maria Pina Simula1, Emilio Usala1, Giorgio La Nasa1
1SC Ematologia e CTMO, Ospedale Businco, ARNAS Brotzu Cagliari, Dipartimento di Scienze Mediche e Sanità Pubblica, Università di Cagliari, Cagliari, Italy
2Data Center and Health Outcomes Research Unit, Italian Group for Adult Hematologic Diseases (GIMEMA), Rome, Italy

Tóm tắt

The impact of splenectomy on health-related quality of life (HRQoL) in patients with immune thrombocytopenia (ITP) remains scarcely explored. Therefore, we evaluated HRQoL with the 36-Item Short-Form Health Survey (SF-36) in an internal cohort of 69 chronic ITP patients, overall and by type of treatment. Of these patients, 26 patients were splenectomized, while other patients were treated medically with thrombopoietin-receptor agonists (TPO-RAs) or immunosuppressive treatment. We also compared HRQoL of the splenectomized patients (internal cohort) with an external cohort of 63 splenectomized ITP patients and the general population. The median follow-up was 10 years (range 1–20). Splenectomized patients had a worse overall HRQoL profile than those who received medical therapy either with TPO-RAs or other treatments (OT), with clinically meaningful differences registered in several domains. These included physical functioning (Δ = − 17.0 and Δ = − 15.2, for TPO-Ras and OT, respectively, p = 0.065), role physical (Δ = − 9.7 and Δ = − 13.8, p = 0.483), and bodily pain (Δ = − 14.2 and Δ = − 18.8, p = 0.053). Compared to the general population, both internal and external splenectomized cohorts had an impaired HRQoL profile. Further studies on HRQoL in splenectomized ITP patients are needed to better understand the long-term impact of this surgical procedure.

Tài liệu tham khảo

Cooper N, Ghanima W (2019) Immune thrombocytopenia. N Engl J Med 381(10):945–955 Provan D, Arnold DM, Bussel JB, Chong BH, Cooper N, Gernsheimer T et al (2019) Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv 3(22):3780–3817 Chaturvedi S, Arnold DM, McCrae KR 2018 Splenectomy for immune thrombocytopenia: down but not out. Blood 15;131(11):1172–82. Neunert C, Lim W, Crowther M, Cohen A, Solberg L, Crowther MA et al (2011) The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 117(16):4190–4207 Efficace F, Mandelli F, Fazi P, Santoro C, Gaidano G, Cottone F et al (2016) Health-related quality of life and burden of fatigue in patients with primary immune thrombocytopenia by phase of disease. Am J Hematol 91(10):995–1001 Cooper N, Kruse A, Kruse C, Watson S, Morgan M, Provan D et al (2021) Immune thrombocytopenia (ITP) World Impact Survey (I-WISh): impact of ITP on health-related quality of life. Am J Hematol 96(2):199–207 Hill QA, Newland AC (2015) Fatigue in immune thrombocytopenia. Br J Haematol 170(2):141–149 Trotter P, Hill QA (2018) Immune thrombocytopenia: improving quality of life and patient outcomes. Patient Relat Outcome Meas. 9:369–384 Lebioda A, Batscheider A (2015) Health-related quality of life (Hrqol) In splenectomized immune thrombocytopenia (ITP) patients – a targeted literature review. Value Health. 1(18):A676 Snyder CF, Mathias SD, Cella D, Isitt JJ, Wu AW, Young J (2008) Health-related quality of life of immune thrombocytopenic purpura patients: results from a web-based survey. Curr Med Res Opin 24(10):2767–2776 George JN, Mathias SD, Go RS, Guo M, Henry DH, Lyons R et al (2009) Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials. Br J Haematol 144(3):409–415 Suvajdzic N, Zivkovic R, Djunic I, Vidovic A, Markovic O, Marisavljevic D et al (2014) Health-related quality of life in adult patients with chronic immune thrombocytopenia in Serbia. Platelets 25(6):467–469 Newton JL, Reese JA, Watson SI, Vesely SK, Bolton-Maggs PHB, George JN et al (2011) Fatigue in adult patients with primary immune thrombocytopenia. Eur J Haematol 86(5):420–429 Apolone G, Mosconi P (1998) The Italian SF-36 Health Survey: translation, validation and norming. J Clin Epidemiol 51(11):1025–1036 Sloan J, Symonds T, Vargas-Chanes D, Fridley B (2003) Practical guidelines for assessing the clinical significance of health-related quality of life changes within clinical trials. Drug Inf J 37(1):23–31 Colangelo KJ, Pope JE, Peschken C (2009) The minimally important difference for patient reported outcomes in systemic lupus erythematosus including the HAQ-DI, pain, fatigue, and SF-36. J Rheumatol 36(10):2231–2237 Mathias SD, Bussel JB, George JN, McMillan R, Okano GJ, Nichol JL (2007) A disease-specific measure of health-related quality of life in adults with chronic immune thrombocytopenic purpura: psychometric testing in an open-label clinical trial. Clin Ther 29(5):950–962 Rodeghiero F (2018) A critical appraisal of the evidence for the role of splenectomy in adults and children with ITP. Br J Haematol 181(2):183–195